Will the latest drive to create a UK environment that rewards medtech innovation with swift adoption and appropriate reimbursement solve the problems that the industry has been highlighting for a decade or more? The fervent hope is that the mechanisms and support offered in recent government initiatives, including the Accelerated Access Review (AAR), will provide lasting answers and represent more than good intentions, well written.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?